Drug Type TCR therapy |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Miltenyi Biomedicine GmbHStartup |
Active Organization Miltenyi Biomedicine GmbHStartup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute myeloid leukemia with mutated NPM1 | Phase 2 | NL | Miltenyi Biomedicine GmbHStartup | 01 Aug 2024 |
Acute Myeloid Leukemia | Preclinical | DE | Miltenyi Biomedicine GmbHStartup | 12 Aug 2022 |